Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 29

1.

The albumin-bilirubin grade uncovers the prognostic relationship between hepatic reserve and immune dysfunction in HIV-associated hepatocellular carcinoma.

Pinato DJ, Sharma R, Citti C, Platt H, Ventura-Cots M, Allara E, Chen TY, Dalla Pria A, Jain M, Mínguez B, Kikuchi L, Kaufman West E, Merli M, Kaplan DE, Hasson H, Marks K, Nelson M, Núñez M, Aytaman A, Bower M, Bräu N; Liver Cancer in HIV Study Group.

Aliment Pharmacol Ther. 2018 Jan;47(1):95-103. doi: 10.1111/apt.14356. Epub 2017 Oct 16.

PMID:
29034998
2.

Complete response under sorafenib in patients with hepatocellular carcinoma: Relationship with dermatologic adverse events.

Rimola J, Díaz-González Á, Darnell A, Varela M, Pons F, Hernandez-Guerra M, Delgado M, Castroagudin J, Matilla A, Sangro B, Rodriguez de Lope C, Sala M, Gonzalez C, Huertas C, Minguez B, Ayuso C, Bruix J, Reig M.

Hepatology. 2017 Sep 12. doi: 10.1002/hep.29515. [Epub ahead of print]

3.

Clinical characteristics of hepatocellular carcinoma in Spain. Comparison with the 2008-2009 period and analysis of the causes of diagnosis out of screening programs. Analysis of 686 cases in 73 centers.

Rodríguez de Lope C, Reig M, Matilla A, Ferrer MT, Dueñas E, Mínguez B, F Castroagudín J, Ortiz I, Pascual S, Lledó JL, Gallego A, Arenas JI, Aracil C, Forne M, Muñoz C, Pons F, Sala M, Iñarrairaegui M, Martin-Llahi M, Andreu V, Garre C, Rendón P, Fuentes J, Crespo J, Rodríguez M, Bruix J, Varela M; en representación del Grupo de Estudio de Cáncer Hepático (GECH).

Med Clin (Barc). 2017 Jul 21;149(2):61-71. doi: 10.1016/j.medcli.2016.12.048. Epub 2017 Mar 7. English, Spanish.

PMID:
28279536
4.

High HCV subtype heterogeneity in a chronically infected general population revealed by high-resolution hepatitis C virus subtyping.

Rodriguez-Frias F, Nieto-Aponte L, Gregori J, Garcia-Cehic D, Casillas R, Tabernero D, Homs M, Blasi M, Vila M, Chen Q, Vargas V, Castells L, Viladomiu L, Genesca J, Minguez B, Augustin S, Riveiro-Barciela M, Carbonell J, Perales C, Soria ME, Asensio M, Llorens M, Ordeig L, Godoy C, Buti M, Esteban R, Pumarola T, Esteban JI, Quer J.

Clin Microbiol Infect. 2017 Oct;23(10):775.e1-775.e6. doi: 10.1016/j.cmi.2017.02.007. Epub 2017 Feb 10.

PMID:
28192235
5.

Impact of ornithine phenylacetate (OCR-002) in lowering plasma ammonia after upper gastrointestinal bleeding in cirrhotic patients.

Ventura-Cots M, Concepción M, Arranz JA, Simón-Talero M, Torrens M, Blanco-Grau A, Fuentes I, Suñé P, Alvarado-Tapias E, Gely C, Roman E, Mínguez B, Soriano G, Genescà J, Córdoba J.

Therap Adv Gastroenterol. 2016 Nov;9(6):823-835. Epub 2016 Jul 26.

6.

Randomized phase II placebo controlled study of codrituzumab in previously treated patients with advanced hepatocellular carcinoma.

Abou-Alfa GK, Puig O, Daniele B, Kudo M, Merle P, Park JW, Ross P, Peron JM, Ebert O, Chan S, Poon TP, Colombo M, Okusaka T, Ryoo BY, Minguez B, Tanaka T, Ohtomo T, Ukrainskyj S, Boisserie F, Rutman O, Chen YC, Xu C, Shochat E, Jukofsky L, Reis B, Chen G, Di Laurenzio L, Lee R, Yen CJ.

J Hepatol. 2016 Aug;65(2):289-95. doi: 10.1016/j.jhep.2016.04.004. Epub 2016 Apr 13.

PMID:
27085251
7.

Unique genomic profile of fibrolamellar hepatocellular carcinoma.

Cornella H, Alsinet C, Sayols S, Zhang Z, Hao K, Cabellos L, Hoshida Y, Villanueva A, Thung S, Ward SC, Rodriguez-Carunchio L, Vila-Casadesús M, Imbeaud S, Lachenmayer A, Quaglia A, Nagorney DM, Minguez B, Carrilho F, Roberts LR, Waxman S, Mazzaferro V, Schwartz M, Esteller M, Heaton ND, Zucman-Rossi J, Llovet JM.

Gastroenterology. 2015 Apr;148(4):806-18.e10. doi: 10.1053/j.gastro.2014.12.028. Epub 2014 Dec 31.

8.

Phylogenetic demonstration of hepatitis E infection transmitted by pork meat ingestion.

Riveiro-Barciela M, Mínguez B, Gironés R, Rodriguez-Frías F, Quer J, Buti M.

J Clin Gastroenterol. 2015 Feb;49(2):165-8. doi: 10.1097/MCG.0000000000000113.

PMID:
24637729
9.

Prognostic gene expression signature for patients with hepatitis C-related early-stage cirrhosis.

Hoshida Y, Villanueva A, Sangiovanni A, Sole M, Hur C, Andersson KL, Chung RT, Gould J, Kojima K, Gupta S, Taylor B, Crenshaw A, Gabriel S, Minguez B, Iavarone M, Friedman SL, Colombo M, Llovet JM, Golub TR.

Gastroenterology. 2013 May;144(5):1024-30. doi: 10.1053/j.gastro.2013.01.021. Epub 2013 Jan 17.

10.

Single HCC in cirrhotic patients: liver resection or liver transplantation? Long-term outcome according to an intention-to-treat basis.

Sapisochin G, Castells L, Dopazo C, Bilbao I, Minguez B, Lázaro JL, Allende H, Balsells J, Caralt M, Charco R.

Ann Surg Oncol. 2013 Apr;20(4):1194-202. doi: 10.1245/s10434-012-2655-1. Epub 2012 Sep 11.

PMID:
22965574
11.

Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib.

Lachenmayer A, Alsinet C, Savic R, Cabellos L, Toffanin S, Hoshida Y, Villanueva A, Minguez B, Newell P, Tsai HW, Barretina J, Thung S, Ward SC, Bruix J, Mazzaferro V, Schwartz M, Friedman SL, Llovet JM.

Clin Cancer Res. 2012 Sep 15;18(18):4997-5007. Epub 2012 Jul 18.

12.

Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib.

Lachenmayer A, Toffanin S, Cabellos L, Alsinet C, Hoshida Y, Villanueva A, Minguez B, Tsai HW, Ward SC, Thung S, Friedman SL, Llovet JM.

J Hepatol. 2012 Jun;56(6):1343-50. doi: 10.1016/j.jhep.2012.01.009. Epub 2012 Feb 6.

13.

Diagnostic and prognostic molecular markers in hepatocellular carcinoma.

Mínguez B, Lachenmayer A.

Dis Markers. 2011;31(3):181-90. doi: 10.3233/DMA-2011-0841. Review.

14.

Gene-expression signature of vascular invasion in hepatocellular carcinoma.

Mínguez B, Hoshida Y, Villanueva A, Toffanin S, Cabellos L, Thung S, Mandeli J, Sia D, April C, Fan JB, Lachenmayer A, Savic R, Roayaie S, Mazzaferro V, Bruix J, Schwartz M, Friedman SL, Llovet JM.

J Hepatol. 2011 Dec;55(6):1325-31. doi: 10.1016/j.jhep.2011.02.034. Epub 2011 Apr 13.

15.

Effects of branched-chain amino acids supplementation in patients with cirrhosis and a previous episode of hepatic encephalopathy: a randomized study.

Les I, Doval E, García-Martínez R, Planas M, Cárdenas G, Gómez P, Flavià M, Jacas C, Mínguez B, Vergara M, Soriano G, Vila C, Esteban R, Córdoba J.

Am J Gastroenterol. 2011 Jun;106(6):1081-8. doi: 10.1038/ajg.2011.9. Epub 2011 Feb 15.

PMID:
21326220
16.

MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a.

Toffanin S, Hoshida Y, Lachenmayer A, Villanueva A, Cabellos L, Minguez B, Savic R, Ward SC, Thung S, Chiang DY, Alsinet C, Tovar V, Roayaie S, Schwartz M, Bruix J, Waxman S, Friedman SL, Golub T, Mazzaferro V, Llovet JM.

Gastroenterology. 2011 May;140(5):1618-28.e16. doi: 10.1053/j.gastro.2011.02.009. Epub 2011 Feb 13.

17.

IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage.

Tovar V, Alsinet C, Villanueva A, Hoshida Y, Chiang DY, Solé M, Thung S, Moyano S, Toffanin S, Mínguez B, Cabellos L, Peix J, Schwartz M, Mazzaferro V, Bruix J, Llovet JM.

J Hepatol. 2010 Apr;52(4):550-9. doi: 10.1016/j.jhep.2010.01.015. Epub 2010 Feb 13.

18.

Molecular classification and novel targets in hepatocellular carcinoma: recent advancements.

Hoshida Y, Toffanin S, Lachenmayer A, Villanueva A, Minguez B, Llovet JM.

Semin Liver Dis. 2010 Feb;30(1):35-51. doi: 10.1055/s-0030-1247131. Epub 2010 Feb 19. Review.

19.

Hepatocellular carcinoma: novel molecular approaches for diagnosis, prognosis, and therapy.

Villanueva A, Minguez B, Forner A, Reig M, Llovet JM.

Annu Rev Med. 2010;61:317-28. doi: 10.1146/annurev.med.080608.100623. Review.

20.

Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo.

Newell P, Toffanin S, Villanueva A, Chiang DY, Minguez B, Cabellos L, Savic R, Hoshida Y, Lim KH, Melgar-Lesmes P, Yea S, Peix J, Deniz K, Fiel MI, Thung S, Alsinet C, Tovar V, Mazzaferro V, Bruix J, Roayaie S, Schwartz M, Friedman SL, Llovet JM.

J Hepatol. 2009 Oct;51(4):725-33. doi: 10.1016/j.jhep.2009.03.028. Epub 2009 Jun 12.

21.

Pathogenesis of hepatocellular carcinoma and molecular therapies.

Mínguez B, Tovar V, Chiang D, Villanueva A, Llovet JM.

Curr Opin Gastroenterol. 2009 May;25(3):186-94. doi: 10.1097/MOG.0b013e32832962a1. Review.

PMID:
19387255
22.

Pivotal role of mTOR signaling in hepatocellular carcinoma.

Villanueva A, Chiang DY, Newell P, Peix J, Thung S, Alsinet C, Tovar V, Roayaie S, Minguez B, Sole M, Battiston C, Van Laarhoven S, Fiel MI, Di Feo A, Hoshida Y, Yea S, Toffanin S, Ramos A, Martignetti JA, Mazzaferro V, Bruix J, Waxman S, Schwartz M, Meyerson M, Friedman SL, Llovet JM.

Gastroenterology. 2008 Dec;135(6):1972-83, 1983.e1-11. doi: 10.1053/j.gastro.2008.08.008. Epub 2008 Aug 20.

23.

Focal gains of VEGFA and molecular classification of hepatocellular carcinoma.

Chiang DY, Villanueva A, Hoshida Y, Peix J, Newell P, Minguez B, LeBlanc AC, Donovan DJ, Thung SN, Solé M, Tovar V, Alsinet C, Ramos AH, Barretina J, Roayaie S, Schwartz M, Waxman S, Bruix J, Mazzaferro V, Ligon AH, Najfeld V, Friedman SL, Sellers WR, Meyerson M, Llovet JM.

Cancer Res. 2008 Aug 15;68(16):6779-88. doi: 10.1158/0008-5472.CAN-08-0742.

24.

Hepatic encephalopathy.

Córdoba J, Mínguez B.

Semin Liver Dis. 2008 Feb;28(1):70-80. doi: 10.1055/s-2008-1040322. Review.

PMID:
18293278
25.

Decreased white matter lesion volume and improved cognitive function after liver transplantation.

Rovira A, Mínguez B, Aymerich FX, Jacas C, Huerga E, Córdoba J, Alonso J.

Hepatology. 2007 Nov;46(5):1485-90.

PMID:
17929307
26.

Decrease in the volume of white matter lesions with improvement of hepatic encephalopathy.

Mínguez B, Rovira A, Alonso J, Córdoba J.

AJNR Am J Neuroradiol. 2007 Sep;28(8):1499-500.

27.

Noncirrhotic portal vein thrombosis exhibits neuropsychological and MR changes consistent with minimal hepatic encephalopathy.

Mínguez B, García-Pagán JC, Bosch J, Turnes J, Alonso J, Rovira A, Córdoba J.

Hepatology. 2006 Apr;43(4):707-14.

PMID:
16557541
28.

Treatment of hepatic encephalopathy.

Córdoba J, Mínguez B, Vergara M.

Lancet. 2005 Apr 16-22;365(9468):1384-5; author reply 1385-6. No abstract available.

PMID:
15836879
29.

[Fever due to Epstein-Barr virus infection in Crohns disease].

Lobo B, Mínguez B, Molero X, Casellas F.

Med Clin (Barc). 2003 May 10;120(17):677-8. Spanish. No abstract available.

PMID:
12747820

Supplemental Content

Loading ...
Support Center